Royal Bank of Canada’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-184
| Closed | – | – | 7123 |
|
|
2018
Q1 | $0 | Sell |
184
-13,667
| -99% | -$12.6K | ﹤0.01% | 7302 |
|
|
2017
Q4 | $18K | Buy |
13,851
+11,667
| +534% | +$19K | ﹤0.01% | 5648 |
|
|
2017
Q3 | $5K | Sell |
2,184
-142
| -6% | -$347 | ﹤0.01% | 6453 |
|
|
2017
Q2 | $7K | Sell |
2,326
-504
| -18% | -$1.51K | ﹤0.01% | 5963 |
|
|
2017
Q1 | $10K | Buy |
2,830
+2,287
| +421% | +$9.03K | ﹤0.01% | 6000 |
|
|
2016
Q4 | $1K | Sell |
543
-147
| -21% | -$346 | ﹤0.01% | 6600 |
|
|
2016
Q3 | $2K | Sell |
690
-30
| -4% | -$113 | ﹤0.01% | 6240 |
|
|
2016
Q2 | $3K | Sell |
720
-110
| -13% | -$497 | ﹤0.01% | 6116 |
|
|
2016
Q1 | $5K | Sell |
830
-359
| -30% | -$4.66K | ﹤0.01% | 5956 |
|
|
2015
Q4 | $20K | Sell |
1,189
-1,105
| -48% | -$26.3K | ﹤0.01% | 5729 |
|
|
2015
Q3 | $48K | Buy |
2,294
+142
| +7% | +$4.87K | ﹤0.01% | 5157 |
|
|
2015
Q2 | $107K | Buy |
2,152
+602
| +39% | +$36K | ﹤0.01% | 4791 |
|
|
2015
Q1 | $121K | Sell |
1,550
-15,927
| -91% | -$988K | ﹤0.01% | 4519 |
|
|
2014
Q4 | $1.06M | Buy |
17,477
+423
| +2% | +$21.2K | ﹤0.01% | 2870 |
|
|
2014
Q3 | $726K | Buy |
17,054
+1,566
| +10% | +$84.1K | ﹤0.01% | 3111 |
|
|
2014
Q2 | $957K | Buy |
15,488
+1,646
| +12% | +$95.7K | ﹤0.01% | 2874 |
|
|
2014
Q1 | $900K | Buy |
13,842
+1,360
| +11% | +$92K | ﹤0.01% | 2861 |
|
|
2013
Q4 | $703K | Sell |
12,482
-1,576
| -11% | -$88.6K | ﹤0.01% | 3143 |
|
|
2013
Q3 | $862K | Buy |
14,058
+12,408
| +752% | +$840K | ﹤0.01% | 2897 |
|
|
2013
Q2 | $97K | Buy |
+1,650
| New | +$102K | ﹤0.01% | 4329 |
|
Other funds holding OREX
Royal Bank of Canada's OREX Position: Q2 2018 in Review
Royal Bank of Canada sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 184 shares.
Royal Bank of Canada first reported a position in OREX in Q2 2013 and held it in 20 quarters. The position peaked at $1.06M in Q4 2014. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- Royal Bank of Canada reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- Royal Bank of Canada sold 184 Orexigen Therapeutics, Inc. shares in Q2 2018.
- Royal Bank of Canada first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
- Royal Bank of Canada's Orexigen Therapeutics, Inc. position peaked at $1.06M in Q4 2014.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on Royal Bank of Canada's 13F filing for Q2 2018, filed 14 Aug 2018.